Eliquis Approved for People With Non-Valvular Atrial Fibrillation

To help prevent stroke and deadly blood clots

THURSDAY, Jan. 3 (HealthDay News) -- The anticoagulant Eliquis (apixaban) has been approved by the U.S. Food and Drug Administration to help prevent stroke and dangerous blood clots in people with atrial fibrillation that isn't caused by a heart valve problem.

Eliquis was evaluated in a clinical study of more than 18,000 people. People who took Eliquis had fewer strokes than those who took warfarin, the FDA said. As with similar drugs, the most frequent serious reaction to Eliquis was significant bleeding, the agency added.

Eliquis should not be taken by people with prosthetic heart valves, or by people whose atrial fibrillation is caused by a heart valve problem, the FDA said.

The drug is produced by Bristol-Myers Squibb, based in Princeton, N.J.

More Information

Copyright © 2013 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles

Debunking Three Rape Myths
Journal of Forensic Nursing, October/December 2014
Expires: 12/31/2016 CE:2.5 $24.95


Drug updates and approvals: 2014 in review
The Nurse Practitioner, 13December 2014
Expires: 12/31/2016 CE:3 $27.95


Can Food Processing Enhance Cancer Protection?
Nutrition Today, September/October 2014
Expires: 10/31/2016 CE:2 $21.95


More CE Articles

Subscribe to Recommended CE

Recommended Nursing Articles Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events